Company intelligence / Profile preview

Cellvera Asia

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

Cellvera is a biopharmaceutical company dedicated to the development and commercialization of antiviral therapies for life-threatening viral diseases. The company is best known for holding the exclusive rights to Avigan (favipiravir) in numerous global markets outside of Japan, Russia, and China. Cellvera focuses on addressing unmet medical needs in infectious diseases, including COVID-19 and various strains of influenza. Through strategic manufacturing and distribution partnerships, the company aims to provide broad access to essential antiviral medications worldwide.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Fujifilm Toyama ChemicalDr. Reddy's LaboratoriesAppili Therapeutics

Beyond the preview

Go deeper on Cellvera Asia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellvera Asia.

Explore the full profile